Oct 09, 2025
ESSA Announces Completion of Arrangement with XenoTherapeutics
Oct 06, 2025
ESSA Securityholders Approve Acquisition by XenoTherapeutics
May 08, 2025
ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
Mar 06, 2025
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
Feb 11, 2025
ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024
Dec 17, 2024
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Oct 31, 2024
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Sep 13, 2024
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
Sep 11, 2024
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
Aug 05, 2024
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
Jul 08, 2024
ESSA Pharma to Present at the JonesHealthcare Seaside Summit
May 30, 2024
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
May 14, 2024
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
Apr 09, 2024
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Mar 07, 2024
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
Feb 13, 2024
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
Feb 06, 2024
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan 25, 2024
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Feb 25, 2021
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
Feb 22, 2021
ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock